WEBINAR Improve efficiency and return on investment by adopting molecular spectroscopy techniques in pharma manufacturing

Nitrosamines are potential mutagens and need to be controlled in human drug products. Recently, nitrosamine contamination of high-profile drugs has prompted numerous recalls, and increased regulatory assessments for marketed products.

Single cell cloning (SCC) is a critical and high-value process for an increasing number of applications including cell engineering; stable cell lines for therapeutic mAbs and biosimilars; vector production for gene therapy; and many more. During this webinar, Tom Kelly from Janssen (part of Johnson & Johnson) will talk about his use of Solentim’s VIPS™ (Verified in-situ Plate Seeding) system, the world’s first All-in-One Single Cell Cloning System. He will explain why Janssen moved away from older generation CLD technology using Clonepix, which was based on detecting and picking high-producer clones in semi-solid media.

Using directed integration of antibody genes by CRISPR/Cas9 and TALENs, the construction of large libraries in mammalian cells containing a single antibody gene/cell has been achieved. This accomplishment has enabled the construction of libraries containing millions of monoclonal, stable, cell lines displaying IgG-formatted antibodies on their surface, and from which novel, high-affinity binders can be isolated. This technology also allows for the selection of antibodies with improved biophysical properties from libraries of variants.

IIdiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias and life-threatening multi-organ dysfunction.